Related Experiment Video
Updated: Mar 26, 2026

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
Novel pharmaceutical options for treating fibromyalgia
Maria Chiara Gerardi1, Alberto Batticciotto1, Rossella Talotta1
1a Rheumatology Unit , L. Sacco University Hospital , Milan , Italy.
Abstract:
Fibromyalgia is a chronic disorder whose symptoms have a devastating effect on patients' lives as they limit their ability to engage in everyday working and social activities, and make it difficult to maintain normal relationships with family, friends and employers. None of the currently available drugs are fully effective against the whole spectrum of symptoms of pain, fatigue, sleep disturbances and depression, but increasing efforts by the pharmaceutical industry have led to the introduction of new investigational drugs and new formulations of older drugs, as well as studies of the possibility of applying drugs currently used for other diseases. The aim of this review is to summarise the data relating to the new therapeutic options that have become available over the last few years.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Skeletal Muscle Relaxants: Therapeutic Uses

